

Podstawowe zasady diagnostyki i leczenia nadciśnienia tętniczego

prof. dr hab. med. Andrzej Tykarski

1. The Seventh Report of Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VII). JAMA 2003; 289: 2560–2572.
2. 2003 European Society of Hypertension – European Society of Cardiology Guidelines for the management of arterial hypertension. J. Hypertens. 2003; 21:1011–1053.
3. Stanowisko Polskiego Towarzystwa Nadciśnienia Tętniczego: Zasady postępowania w nadciśnieniu tętniczym. Nadciśnienie Tętnicze, 2003; 7: A5–A21.
4. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. Pediatrics, 2004; 114: 555–576

Aktualne spojrzenie na rolę nadciśnienia tętniczego w patogenezie miażdżycy

prof. dr hab. n. farm. Marek Naruszewicz

1. Browatzki M., Larsen D., Pfeiffer C.A. i wsp.: Angiotensin II stimulates matrix metalloproteinase secretion in human vascular smooth muscle cells via nuclear factor-kappaB and activator protein 1 in a redox-sensitive manner. J. Vasc. Res. 2005; 42: 415-423.
2. Metha J.L., Chen J., Hermonat P.L. i wsp.: Lecitin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): A critical player in the development of atherosclerosis and related disorders. Cardiovasc. Res. 2006; 69: 36-45.
3. Zapolska-Downar D., Siennicka A., Chelstowski K. i wsp.: Is there as association between angiotensin-converting enzyme gene polymorphism and functional activation of monocytes and macrophage in young patients with essential hypertension?. Journal of Hypertension 2006; 24: 1565-1573.

Nadciśnienie tętnicze jako przyczyna uszkodzenia nerek i czynnik ryzyka progresji przewlekłej niewydolności nerek

prof. dr hab. n. med. Władysław Sułowicz

1. Agarwal R., Lewis R.R.: Prediction of hypertension in chronic hemodialysis patients. Kidney Int. 2001; 60: 1982.
2. Go A.S., Chertow G.M., Fan D. et al: Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004, 351, 1296.

3. Herlitz H., Harris K., Risler T., Boner G., Bernheim J., Chanard J., Aurell M.: The effects of an ACE inhibitor and a calcium antagonist on the progression of the renal disease: the Nephros Study. *Nephrol. Dial. Transplant.* 2001; 16: 2158.
4. Jacobi J., Schmieder R.E.: Nephroprotection by antihypertensive therapy. *Basic Res. Cardiol.* 1998; 93 (Suppl.2): 109.
5. Mailloux L.U., Levey A.S.: Hypertension in patients with chronic renal disease. *Am. J. Kidney Dis.* 1998; 32 (Suppl.3): S120.
6. Martinez-Maldonado M.: Role of hypertension in the progression of chronic renal disease. *Nephrol. Dial. Transplant.* 2001; 16 (Suppl.1): 63.
7. Ridao N., Luno J., de Vinuesa S.G., Gomez F., Tejedor A., Valderrabano F.: Prevalence of hypertension in renal disease. *Nephrol. Dial. Transplant.* 2001; 16: 70.
8. Tierney W.M., McDonald C.J., Luft F.C.: Renal disease in hypertensive adults: effect of race and type II diabetes mellitus. *Am. J. Kidney Dis.* 1989; 26: 3085.
9. Toto R.D.: Hypertension and kidney literature review 2000. *Clin. Nephrol.* 2002; 51: 253.

Nadciśnienie tętnicze a z zaburzenia gospodarki węglowodanowej

dr hab. med. Dorota Zozulińska

1. Li JJ, Fang CH, Hui RT: Is hypertension an inflammatory disease? *Med. Hypotheses* 2005, 64: 236-246.
2. Mason J, Dickinson H, Nicolson D, Campbell F, Ford G, Williams B: The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. *J Hypertens* 2005, 23: 1777-1781.
3. Opie LH, Schall R: Old antihypertensive and new diabetes. *J Hypertens* 2004, 22: 1453-1458.
4. Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HAW, Holman RR. Additive effects of glycaemia and blood pressure exposure on risk of complications In type 2 diabetes: a prospective observational study (UKPDS75). *Diabetologia* 2006; 49: 1761-1769.

Nadciśnienie tętnicze w neurologii

prof. dr hab. n. med. Andrzej Szczudlik, dr n. med. Agnieszka Słowik

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High

- Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report [published correction appears in JAMA. 2003;290:197]. JAMA. 2003; 289: 2560–2572.
2. Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, Hill M, Howard G, Howard VJ, Jacobs B, Levine SR, Mosca L, Sacco RL, Sherman DG, Wolf PA, del Zoppo GJ. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. *Circulation*. 2001; 103: 163–182.
 3. Neal B, MacMahon S, Chapman N. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. *Lancet*. 2000; 356: 1955–1964.
 4. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published corrections appear in JAMA. 2003;289:178 and JAMA. 2004;18:2196]. JAMA. 2002; 288: 2981–2997.
 5. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH Jr, Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, Williams G, Wittes J, Zanchetti A, Anders RJ; CONVINCENCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003; 289: 2073–2082.
 6. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet*. 2002; 359: 995–1003.
 7. Turnbull F, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. *Lancet*. 2003; 362: 1527–1535.
 8. Black HR, Elliott WJ, Neaton JD, Grandits G, Grambsch P, Grimm RH Jr, Hansson L, Lacouciere Y, Muller J, Sleight P, Weber MA, White WB, Williams G, Wittes J, Zanchetti A, Fakouhi TD, Anders RJ. Baseline characteristics and early blood pressure control in the CONVINCENCE Trial. *Hypertension*. 2001; 37: 12–18.

9. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM, ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). *J Clin Hypertens*. 2002; 4: 393–404.
10. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. *Stroke*. 2003; 34: 2741–2748.
11. Ralph L. Sacco, Robert Adams, Greg Albers, Mark J. Alberts, Oscar Benavente, Karen Furie, Larry B. Goldstein, Philip Gorelick, Jonathan Halperin, Robert Harbaugh, S. Claiborne Johnston, Irene Katzan, Margaret Kelly-Hayes, Edgar J. Kenton, Michael Marks, Lee H. Schwamm, and Thomas Tomsick. Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline. *Stroke*, Feb 2006; 37: 577 - 617.
12. The European Stroke Initiative Executive Committee and the EUSI Writing Committee. European Stroke Initiative Recommendations for Stroke Management-update 2003. *Cerebrovasc Dis*. 2003;16(4):311-37.
13. Adams HP Jr, Adams RJ, Brott T, del Zoppo GJ, Furlan A, Goldstein LB, Grubb RL, Higashida R, Kidwell C, Kwiatkowski TG, Marler JR, Hademenos GJ, for the Stroke Council of the American Stroke Association. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. *Stroke*. 2003; 34: 1056–1083.
14. The European Stroke Initiative Writing Committee and Writing Committee for the EUSI Executive Committee. Recommendations for the management of intracranial haemorrhage - part I: spontaneous intracerebral haemorrhage. *Cerebrovasc Dis*. 2006;22 (4):294-316.
15. Qiu Ch, Winblad B, Fratiglioni L.: The age-dependent relation of blood pressure to cognitive function and dementia. *Lancet Neurology* 2005;4:487-99

Nadciśnienie tętnicze w ciąży

prof. dr hab. med. Kalina Kawecka-Jaszcz

1. Cifkova R., Czarnecka D., Kawecka-Jaszcz K.: Nadciśnienie tętnicze a ciąża. *Choroby*

- Serca i Naczynia 2005, 2, 1-7.
2. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. *J. Hypertens.* 2003; 21: 1011-1053.
 3. Kawecka-Jaszcz K., Czarnecka D., Lubaszewski W.: Nadciśnienie tętnicze u kobiet w ciąży. W: *Choroby serca u kobiet w ciąży*. Red. G. Świątecka i Z. Kornacewicz-Jach, Via Medica, Gdańsk 2006, 26-40.

Kilka uwag na temat ciśnienia tętniczego u dzieci.

dr hab. n. med. Lesław Szydłowski

1. Wszyńska T., Litwin M. Nadciśnienie tętnicze u dzieci i młodzieży. Biblioteka pediatrii, Wydawnictwo Lekarskie PZWL, Warszawa, 2002.
2. The fourth report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. *Pediatrics*, 2004; 114: 555-576
3. Krzych Ł., Kowalska M., Szydłowski L, Markiewicz-Łoskot M.: Ocena wpływu wybranych parametrów noworodków na nieprawidłową dobową zmienność ciśnienia tętniczego u dzieci z nadciśnieniem tętniczym. *Nadciśnienie Tętnicze*, 2006, 10, 30-34.

Terapia osób starszych z nadciśnieniem – nie leczmy milimetrów słupa rtęci!!!

prof. dr hab. Tomasz Grodzicki

1. Zdrojewski T., Bandisz P., Szpakowski P. i wsp. Rozpowszechnienie g³ównych czynników ryzyka chorób uk³adu sercowo-naczyniowego w Polsce. Wyniki badania NATPOL PLUS. *Kardiologia Polska*. 2004; 61:5-26
2. Staessen J.A., Gasowski J., Wang J.G., i wsp. Risk of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. *Lancet* 2000; 355: 865-872
3. Gueyffier F, Bulpitt C, Boissel JP, et al. for the INDANA group. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. *Lancet* 1999;353:793-798.
4. Linholm LH, Carlberg B, Samuelsson O: Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. *Lancet* 2005;366: 1545-1553

. Chory z nadciśnieniem tętniczym w praktyce lekarza rodzinnego

prof. dr hab. Wanda Horst-Sikorska

1. Elżbieta Marcinkowska, Jacek Manitius - Nadciśnienie tętnicze - od rozpoznania do leczenia. *Family Medicine & Primary Care Review* 2005, 7, 2:283-297
2. Fraz A. Mir, Ian B. Wilkinson - Racjonalne podejście do leczenia nadciśnienia tętniczego *Lekarz Rodzinny* Nr 3(91) 2005 str. 272-275
3. Tom Baster, Christine Baster-Brooks - Wysilek fizyczny a nadciśnienie tętnicze *Lekarz Rodzinny* Nr 2(102) 2006 str. 192-199
4. Piotr Tyszko - Zadania medycyny rodzinnej w świetle celów Narodowego Programu Zdrowia Polska *Medycyna Rodzinna (obecnie Family Medicine & Primary Care Review)* 2004, 6, 3:1107-1112